Ämnen: Farmaci

Tagrisso™ (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790m mutation-positive metastatic non-small cell lung cancer

3 Februari 2016 08:04

TAGRISSO™ is the first new medicine to be approved under the European Commission’s expedited process
Approval based on studies showing objective response rate of 66% and median progression-free survival of 9.7 months
Tumour sample or blood test can determine patients likely to benefit from osimertinib
AstraZeneca today announced that the European Commission (EC) has granted conditional m

Lynparza™ (olaparib) granted breakthrough therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer

28 Januari 2016 08:03

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for the oral poly ADP-ribose polymerase (PARP) inhibitor Lynparza™ (olaparib),

AstraZeneca and Incyte announce new lung cancer clinical trial collaboration

11 Januari 2016 13:03

AstraZeneca and Incyte Corporation today announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso® (osimertinib). The combination will be assessed as a second line treatment for patients with EGFR mutation-positive

AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise Immuno-Oncology mRNA Therapeutics™

11 Januari 2016 13:01

Moderna to lead preclinical development; AstraZeneca to lead clinical development; Moderna to co-commercialise and share profits on resulting products in the US
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates

ZURAMPIC® (lesinurad) approved by US FDA for patients with gout

23 December 2015 08:01

​AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved ZURAMPIC®(lesinurad) 200mg tablets in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with gout

TAGRISSO™ (OSIMERTINIB) , LESINURAD OCH BRILIQUE (TICAGRELOR) FÅR POSITIVT UTLÅTANDE FRÅN CHMP I EU

18 December 2015 15:43

AstraZeneca meddelar idag att den europeiska läkemedelsmyndigheten EMA:s rådgivande kommitté CHMP ger positivt besked och rekommenderar godkännande av TAGRISSO™ (AZD9291, osimertinib) och lesinurad, samt ny indikation för BRILIQUE (ticagrelor) 60mg för behandling av patienter som har en historia av hjärtinfarkt och hög risk att få en ytterligare aterotrombotisk händelse.

Durvalumab ATLANTIC trial supports clinical activity and AstraZeneca’s overall immuno-oncology strategy

18 December 2015 08:03

Durvalumab demonstrated clinical activity and durable responses in 3rd-line or later stage NSCLC patients; full data to be presented at a scientific congress in 2016

AstraZeneca enhances long term growth through oncology investment in Acerta Pharma

17 December 2015 08:02

Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor, acalabrutinib Opportunity for first regulatory submissions in haematological malignancies in 2016

AstraZeneca continues strategic investment in China to accelerate delivery of innovative biologics and targeted medicines

16 December 2015 08:34

​Strategic alliance with WuXi AppTec to develop next-generation biologics in China New small molecule development facility; new global hub for Pharmaceutical Development

AstraZeneca to strengthen therapy area franchise through acquisition of Takeda’s respiratory business

16 December 2015 08:18

Acquisition to include non-US rights to roflumilast and will beaccretive to 2016 earnings, contributing to AstraZeneca’s return to growth strategy

Discussions with Acerta Pharma BV

14 December 2015 09:12

Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.
The Company will make a further announcement if and when appropriate.
– ENDS –
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, inn

AstraZeneca i samarbete med nytt svenskt center för proteinforskning för utveckling av nästa generations läkemedel genom sekretomforskning

11 December 2015 08:33

AstraZeneca och koncernens globala forsknings- och utvecklingsbolag för biologiska läkemedel, Medimmune, meddelar idag ett treårigt samarbete med det nybildade forskningscentret Wallenberg Centre for Protein Research (WCPR).

AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US

23 November 2015 08:01

Divestmentfurther sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015

AstraZeneca and Sanofi exchange over 200,000 chemical compounds

20 November 2015 08:02

AstraZeneca and Sanofi today announced a direct exchange of 210,000 compounds from their respective proprietary compound libraries. The swap represents a novel open innovation model between pharmaceutical companies.

AstraZeneca expands technological investment in new Cambridge lead discovery centre

20 November 2015 08:02

AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical

Tagrisso™ (AZD9291) approved by the US FDA for patients with EGFR t790m mutation-positive metastatic non-small cell lung cancer

13 November 2015 16:27

​One of fastest development programmes – from start of clinical trials to approval in just over two and a half years to meet unmet patient need With objective response rate of 59% and duration of response of 12.4 months, TAGRISSO provides important new option for patients

Outtröttlig bröstcancerkämpe får prestigetyngd utmärkelse

13 November 2015 13:19

BRO:s Utmärkelse 2015 tilldelas Helena Janlöv-Remnerud, sjuksköterska och medicinsk lymfterapeut, hemmahörande i Edsbro i Uppland.

PEGASUS-TIMI 54 SUB-ANALYSIS OUTLINES LONG-TERM TOLERABILITY DATA FOR BRILIQUE

13 November 2015 07:45

Data presented at AHA suggests benefit in patients who stayed on Brilique (ticagrelor) treatment.

AstraZeneca presents positive new data on anifrolumab in lupus at American College of Rheumatology Annual Scientific Meeting

10 November 2015 08:03

Anifrolumab met primary and secondary endpoints in Phase II, significantly reducing lupus disease activity compared with placebo across multiple endpoints

AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma

6 November 2015 08:07

AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review